Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361818964> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4361818964 abstract "<p>Supplemental Figures 1-7. Supplemental Figure 1: This figure shows the results of the dose response of human prostate cancer lines to antiandrogen (Enzalutamide) and Docetaxel (1st line taxane chemotherapy) as single agents and in combination treatment. It also describes the effect of AR variants on prostate cancer cell migration. Supplemental Figure 2: This figures describes the findings on the combined effect of Cabazitaxel ( 2nd line taxane chemotherapy) and Enzalutamie (antiandrogen) on AR expression, cellular localization and transcriptional activity ( target gene expression) in androgen-sensitive prostate cancer cells, VCaP. Supplemental Figure 3: This figure shows the results from confocal microscopy analysis on the cellular localization of AR variants, tubulin expression and nuclear presence in Cabazitaxel-resistant prostate cancer cells. Supplemental Figure 4: This Figure indicates the effect of Cabazitaxel treatment on kinesin protein and mRNA expression in androgen-responsive prostate cancer cells VCaP. Supplemental Figure 5: This Figure shows the results from immunofluorescence for detection of centrosomal amplification (pericentrin) in CRPC 22Rv1 cells after Cabazitaxel and antiandrogen treatment. Supplemental Figure 6: This Figure schematically summarizes the therapeutic regimen/dosing for in vivo treatment of pre-clinical transgenic model of prostate cancer with Cabazitaxel and antiandrogens and the consequences of treatment on body weight. Supplementary Figure 7: This Figure schematically describes the therapeutic dosing regimen of Cabazitaxel treatment in prostate cancer human xenograft model (22Rv1 castration resistant prostate cancer) in vivo. It also provides information on the antitumor effect of treatment on tumor growth and body weight of mice.</p>" @default.
- W4361818964 created "2023-04-05" @default.
- W4361818964 creator A5009670051 @default.
- W4361818964 creator A5014905106 @default.
- W4361818964 creator A5023767649 @default.
- W4361818964 creator A5028617589 @default.
- W4361818964 creator A5032769690 @default.
- W4361818964 creator A5086520033 @default.
- W4361818964 date "2023-03-30" @default.
- W4361818964 modified "2023-09-27" @default.
- W4361818964 title "Supplemental figures from Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer" @default.
- W4361818964 doi "https://doi.org/10.1158/0008-5472.22410012" @default.
- W4361818964 hasPublicationYear "2023" @default.
- W4361818964 type Work @default.
- W4361818964 citedByCount "0" @default.
- W4361818964 crossrefType "posted-content" @default.
- W4361818964 hasAuthorship W4361818964A5009670051 @default.
- W4361818964 hasAuthorship W4361818964A5014905106 @default.
- W4361818964 hasAuthorship W4361818964A5023767649 @default.
- W4361818964 hasAuthorship W4361818964A5028617589 @default.
- W4361818964 hasAuthorship W4361818964A5032769690 @default.
- W4361818964 hasAuthorship W4361818964A5086520033 @default.
- W4361818964 hasBestOaLocation W43618189641 @default.
- W4361818964 hasConcept C121608353 @default.
- W4361818964 hasConcept C126322002 @default.
- W4361818964 hasConcept C143998085 @default.
- W4361818964 hasConcept C2776235491 @default.
- W4361818964 hasConcept C2776551883 @default.
- W4361818964 hasConcept C2777511904 @default.
- W4361818964 hasConcept C2777899217 @default.
- W4361818964 hasConcept C2778971682 @default.
- W4361818964 hasConcept C2779322244 @default.
- W4361818964 hasConcept C2780192828 @default.
- W4361818964 hasConcept C2781190966 @default.
- W4361818964 hasConcept C502942594 @default.
- W4361818964 hasConcept C530470458 @default.
- W4361818964 hasConcept C61367390 @default.
- W4361818964 hasConcept C71924100 @default.
- W4361818964 hasConceptScore W4361818964C121608353 @default.
- W4361818964 hasConceptScore W4361818964C126322002 @default.
- W4361818964 hasConceptScore W4361818964C143998085 @default.
- W4361818964 hasConceptScore W4361818964C2776235491 @default.
- W4361818964 hasConceptScore W4361818964C2776551883 @default.
- W4361818964 hasConceptScore W4361818964C2777511904 @default.
- W4361818964 hasConceptScore W4361818964C2777899217 @default.
- W4361818964 hasConceptScore W4361818964C2778971682 @default.
- W4361818964 hasConceptScore W4361818964C2779322244 @default.
- W4361818964 hasConceptScore W4361818964C2780192828 @default.
- W4361818964 hasConceptScore W4361818964C2781190966 @default.
- W4361818964 hasConceptScore W4361818964C502942594 @default.
- W4361818964 hasConceptScore W4361818964C530470458 @default.
- W4361818964 hasConceptScore W4361818964C61367390 @default.
- W4361818964 hasConceptScore W4361818964C71924100 @default.
- W4361818964 hasLocation W43618189641 @default.
- W4361818964 hasLocation W43618189642 @default.
- W4361818964 hasOpenAccess W4361818964 @default.
- W4361818964 hasPrimaryLocation W43618189641 @default.
- W4361818964 hasRelatedWork W1652439388 @default.
- W4361818964 hasRelatedWork W2094570582 @default.
- W4361818964 hasRelatedWork W2111028754 @default.
- W4361818964 hasRelatedWork W2135620818 @default.
- W4361818964 hasRelatedWork W2263206436 @default.
- W4361818964 hasRelatedWork W2315729659 @default.
- W4361818964 hasRelatedWork W2568045406 @default.
- W4361818964 hasRelatedWork W2768013934 @default.
- W4361818964 hasRelatedWork W2901274396 @default.
- W4361818964 hasRelatedWork W4297477309 @default.
- W4361818964 isParatext "false" @default.
- W4361818964 isRetracted "false" @default.
- W4361818964 workType "article" @default.